Brain protein clue reshapes Alzheimer’s spread theory

Scientists have identified a possible route by which Alzheimer’s disease advances through the brain, after finding that a protein normally involved in neuron-to-neuron communication may also carry toxic Tau from damaged cells into healthy ones.

The discovery centres on Arc, a brain protein known to support learning, memory and synaptic plasticity. New laboratory research in mice indicates that Arc can package Tau into tiny extracellular vesicles, allowing the abnormal protein to move between neurons. The finding offers a fresh explanation for how Tau pathology spreads across brain regions as memory loss, confusion and cognitive decline worsen.

Alzheimer’s disease is marked by two major biological features: amyloid plaques outside neurons and Tau tangles inside them. While amyloid has dominated drug development for decades, Tau is closely linked to the progression of symptoms. As Tau becomes misfolded, it forms clumps that disrupt the internal structure of neurons and eventually contribute to cell death.

The latest study, published in Cell, suggests Arc may act as an unwitting carrier. Researchers found that Tau could bind directly to Arc and travel inside extracellular vesicles, the microscopic parcels used by cells to exchange molecular signals. These vesicles can be useful in a healthy brain, but in Alzheimer’s they may provide harmful Tau with a transport system.

The work was led by researchers including Mitali Tyagi and Jason Shepherd, whose laboratory has long studied Arc’s unusual biology. Arc has drawn scientific interest because it behaves in some ways like a domesticated viral protein, forming structures that can move material between cells. That same feature may help explain why it can also assist Tau transmission under disease conditions.

Experiments using mouse models showed that when Arc was absent, Tau was less able to leave diseased neurons in extracellular vesicles. Those vesicles also had reduced seeding potential, meaning they were less capable of triggering Tau aggregation in other cells. The researchers also found Arc and Tau together in vesicles derived from mouse and human brain tissue, strengthening the case that the mechanism may be relevant beyond a single experimental model.

The findings do not mean Arc causes Alzheimer’s disease. Arc is essential for normal brain function, and blocking it broadly could risk damaging memory and cognition. The therapeutic interest lies instead in targeting specific vesicles or interrupting the interaction that allows toxic Tau to hitch a ride. Such an approach could aim to slow spread without eliminating a protein needed by the brain.

That distinction matters because Alzheimer’s treatment remains limited. Anti-amyloid medicines such as lecanemab and donanemab have shifted the field by showing that disease biology can be modified, but their effects are modest, treatment is intensive, and safety monitoring is required because of risks including brain swelling and bleeding. The search for complementary targets has therefore intensified, with Tau, inflammation, vascular health and cellular clearance pathways receiving greater attention.

Dementia affects about 57 million people worldwide, with nearly 10 million new cases each year. Alzheimer’s disease accounts for an estimated 60 to 70 per cent of dementia cases. The economic burden is also rising, with global dementia costs estimated at $1.3 trillion in 2019, much of it linked to unpaid care provided by families.

The Arc finding fits a wider trend in Alzheimer’s research: a move away from viewing the disease as a single-protein disorder and towards mapping the systems that allow pathology to travel through the brain. Imaging studies, post-mortem analyses and computational models have increasingly shown that Tau appears to spread along connected neural networks rather than appearing randomly.

Scientists caution that mouse findings often fail to translate cleanly into human therapies. Alzheimer’s develops over many years, and human brains are shaped by age, genetics, vascular disease, inflammation and other conditions that are difficult to recreate fully in animals. Any treatment based on blocking Tau movement would also need to act early enough, before widespread brain damage has occurred.